變化即將來臨，歐洲藥品質(zhì)量管理局?(EDQM)近日宣布，歐洲藥典許可和出版模式即將迎來重大更新。

即將到來的變化將使歐洲藥典的訪問和使用變得更容易，更環(huán)保，并能更好地滿足您多年來的需求和要求。

從第?EP12.1開始，歐洲藥典將完全在線提供，所有文本都可在改進的、用戶友好的平臺上供訂閱者使用。會用一種更直觀的方法，更現(xiàn)代化的界面，快速高效地訪問所需的內(nèi)容，具有更強的搜索功能、高效的儀表板、新的過濾器和屬性等等。

新的年度版本由三卷組成（編號12.1-12.3），對應(yīng)2025年歐洲藥典委員會會議在其中通過的新文本和修訂文本，將取代以前三年一個版本，八個增補的更新周期。

此外，將引入365天的許可模式，簡化許可管理。歐洲藥典將過渡到新的平臺和出版模式，以便順利進行這些更改。

所有第11版的訂閱將在過渡期內(nèi)有效，直至2025年底。

自2026年1月1日起，僅新平臺可用。

我公司是歐洲藥典委員會（EDQM）簽約分銷商(以旗下公司名義)，具體資質(zhì)可聯(lián)系我公司查看。

我司將及時推送關(guān)于歐洲藥典的最新消息，也歡迎廣大客戶聯(lián)系我們訂閱購買。

注意：基于稅務(wù)要求，有關(guān)進口產(chǎn)品的銷售我司可能會用旗下公司抬頭與您簽訂合同、結(jié)算和開票，以方便報稅記賬，請知悉。

歐洲藥品質(zhì)量管理局通知原文

Change is in the air, and the European Directorate for the Quality of Medicines & HealthCare (EDQM) would like to give you, as an important stakeholder, advance notice of the improvements coming to the European Pharmacopoeia licencing and publication models. The upcoming changes will make it easier to access and use, more environmentally friendly and better able to meet your requirements and needs for many years to come.

Starting with Issue 12.1, the European Pharmacopoeia will be available exclusively online, with all texts available to subscribers on an improved, user-friendly platform. You will discover a more visual approach with a modern, intuitive interface for quick and efficient access to the content you need, featuring enhanced search capabilities, a time-saving dashboard, new filters and attributes, and much more.

An annual edition consisting of three issues (numbered 12.1 to 12.3), corresponding to the European Pharmacopoeia Commission sessions in 2025 at which new and revised texts are adopted, will replace the former three-year cycle comprising one edition and eight supplements. Likewise, a 365-day licencing model will be introduced, with simplified licence management.

The European Pharmacopoeia will transition to the new platform and publication models to ease in the changes. All subscriptions to the 11th Edition will remain valid during the transitional period until the end of 2025. As of 1 January 2026, only the new platform will be available.